ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 136

The 7-Joints Musculoskeletal Ultrasound Score (US7 score) Predicts Therapeutic Change in Patients with Early Rheumatoid Arthritis

Sarah Ohrndorf1, Philipp Daniel Oberdorfer2, Lien Le3, Ulrich Mansmann3, Lisa Ines Sprenger2, Thomas Häupl4, Sandra Hermann2, Gabriela Schmittat2, Silvia Pade2, GR Burmester5, Anne-Marie Glimm2 and Marina Backhaus6, 1Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, 3Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität Munich, Munich, Germany, 4Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 5Charité – University Medicine Berlin, Berlin, Germany, 6Department of Rheumatology & Immunology, University Medicine Charit, Berlin, Germany

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, Rheumatoid arthritis (RA), synovitis and ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Treatment decisions in patients with Rheumatoid Arthritis (RA) after the “Treat to Target (T2T)” – principle is widely recommended, as this management strategy leads to a better outcome (1). Recently, the additional use of musculoskeletal ultrasound (US) within the T2T-strategy was recommended (2). However, superior value in terms of outcome of US- compared to the use of (only) clinical scores-guided strategy has not been demonstrated (3). To assess potential clinical and imaging markers which may have the capacity to predict changes of therapy.

Methods: In this ongoing observational study (‘Arthromark’), patients with early RA (disease duration ≤2 years) are included before therapy initiation/change and amongst others parameters are assessed by the clinical score DAS28(ESR) and by all items of the 7-joint US score (US7 score; (4)) at baseline (before therapy initiation/change), and after 1.5, 3, 6, and 12 months. At each visit, treatment decision of the antirheumatic therapy is performed according to the T2T-principle. Treatment change contains any modification of the antirheumatic therapies during the 12 months follow-up, i.e. doses escalation, combination of conventional DMARD therapies, and additional/change to biologic therapies. The following two patient groups were considered in the analysis: 1) patients that underwent any change in the antirheumatic therapy, and 2) patients that underwent none of the changes mentioned above. This analysis aimed to investigate the association between this change and the clinical (DAS28) and the ultrasound (US7) parameters at baseline. The differences between these two patient groups regarding baseline DAS28(ESR) as well as the ultrasound scores were examined applying statistical tests (Mann-Whitney-U test for continuous variables, χ2test for categorical variables). The significance level was 0.05, which was not adjusted for multiple testing. Furthermore, ROC analysis was performed to investigate the ability of these baseline variables in discriminating the two patient groups.

Results: 74 patients were included in the analysis (average age 52.37 years; 75.68% female). On average, time since first diagnosis was about half a year (max. 2.03 years). At baseline, DAS28(ESR) was 5.14 (min. 3.37, max. 7.57) on average. No statistically significant difference was shown between the two groups regarding baseline DAS28(ESR), however in terms of the baseline US7 synovitis B-mode score, the US7 synovitis Power Doppler score, and the US7 erosion score (Figure 1). These results agree with the results of the ROC analyses (Figure 2), where the AUC of the baseline US7 synovitis B-mode score, the US7 synovitis Power Doppler score, and the US7 erosion score were significantly different from 0.5, indicating that these variables can discriminate patients with and without therapeutic change well enough. According to the ROC analyses, DAS28(ESR) and the US7 tenosynovitis scores (B-mode and Power Doppler) show relatively poorer discriminating performance.

Conclusion: These analyses give a quantitative insight into the association between DAS28(ESR) and US7 score measurements at baseline and any therapeutic change during the course of the study. The results suggest that the synovitis ultrasound scores (in B-mode and Power Doppler) and the erosion score, in contrast to DAS28(ESR), might be able to predict the therapeutic change during the treatment course of patients.

References: [1] Smolen J, et al. Ann Rheum Dis 2016;75:3–15. [2] Horton S, et al. Rheumatology 2016 Published Online First [3] Dale J, et al. Ann Rheum Dis. Mar 29 2016. [4] Backhaus M, et al. Arthritis Rheum 2009; 61;1194-1201


Disclosure: S. Ohrndorf, None; P. D. Oberdorfer, None; L. Le, None; U. Mansmann, None; L. I. Sprenger, None; T. Häupl, None; S. Hermann, None; G. Schmittat, None; S. Pade, None; G. Burmester, UCB, 2,AbbVie, 5,BMS, 5,Hexal, 5,Janssen Pharmaceutica Product, L.P., 5,Lilly, 5,MSD, 5,MadImmune, 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,AbbVie, 8,BMS, 8,Hexal, 8,MSD, 8,Novartis Pharmaceutical Corporation, 8,Pfizer Inc, 8,Roche Pharmaceuticals, 8; A. M. Glimm, None; M. Backhaus, None.

To cite this abstract in AMA style:

Ohrndorf S, Oberdorfer PD, Le L, Mansmann U, Sprenger LI, Häupl T, Hermann S, Schmittat G, Pade S, Burmester G, Glimm AM, Backhaus M. The 7-Joints Musculoskeletal Ultrasound Score (US7 score) Predicts Therapeutic Change in Patients with Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-7-joints-musculoskeletal-ultrasound-score-us7-score-predicts-therapeutic-change-in-patients-with-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-7-joints-musculoskeletal-ultrasound-score-us7-score-predicts-therapeutic-change-in-patients-with-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology